AbbVie forays into obesity market with up to $2.2B Gubra license deal

AbbVie (NYSE:ABBV) has entered into a license deal with Danish biotech Gubra A/S to develop the latter’s experimental obesity treatment.

Under the terms of the agreement, AbbVie (NYSE:ABBV) will lead development and commercialization activities of GUB014295 globally. The partnership